NEOPLASMS

This program provided access to the experimental drug taletrectinib for patients with advanced ROS1-positive lung cancer who had run out of approved treatment options and couldn't join regular clinical trials. The program was designed for people whose cancer had spread and who co…

This large Phase 3 study is testing whether adding the immunotherapy drug dostarlimab to standard chemotherapy helps women with advanced or recurrent endometrial cancer live longer without their cancer getting worse. The trial involves 785 participants who will receive either the…

This study is testing a combination of three cancer drugs for people whose advanced colorectal cancer has spread and has a specific BRAF gene mutation, and whose first treatment has stopped working. The goal is to see if this combination can shrink tumors and control the cancer f…

This is a first-in-human study to test the safety of a new type of engineered immune cell therapy for adults with specific lymphomas that have returned or not responded to prior treatments. Researchers modify a patient's own T-cells to better recognize and attack cancer cells car…

This early-stage study is testing a new way to give the cancer drug amivantamab—as an injection under the skin instead of through an IV. It aims to find a safe and effective dose for this injection method in people with advanced solid tumors that have not responded to other treat…

This study aimed to test a new treatment for children whose aggressive brain tumors had returned. The treatment involved injecting a specially engineered virus directly into the tumor, followed by a single low dose of radiation. The goal was to see if this combination could help …

This study is testing a new drug called E7386, given in combination with other cancer medications, for people with advanced solid tumors including endometrial, liver, and colorectal cancers. The main goals are to find the safest and most effective dose and to see how well the com…

This is the first-ever study in humans of an experimental drug called remzistotug for people with advanced solid tumors. It aims to find a safe dose and see how the body handles the drug, both alone and when combined with other cancer treatments. The trial is for patients with sp…

This early-stage study is testing a new cell-based immunotherapy called ACIT-1 in adults with cancer. The main goals are to find the safest dose and see if the treatment can help the patient's own immune system recognize and attack cancer cells. About half of the participants wil…

This is the first study in people to test a new cancer drug called GSK6097608. It aims to find a safe dose and see how the body handles the drug when given alone or combined with other cancer treatments. The study includes about 107 adults with advanced solid tumors that have not…

This study tests whether genetically modified immune cells can safely shrink tumors in people with advanced synovial sarcoma or liposarcoma. Researchers collect patients' own T-cells, engineer them to recognize cancer proteins, then infuse them back into the body. The trial is fo…

This study is testing a personalized cell therapy called Lete-Cel for people with advanced synovial sarcoma or myxoid/round cell liposarcoma. Doctors take a patient's own immune cells, modify them to target a specific protein found on these cancer cells, and infuse them back. The…

This is a first-in-human study to find a safe dose and see how the body processes a new oral drug called ATV-1601. It is being tested in adults with advanced solid tumors, including certain breast cancers, that have a specific genetic change called an AKT1 E17K mutation. The main…

This early-stage study is testing a new oral drug called GSK4524101, both by itself and combined with an existing cancer drug (niraparib), in adults with advanced solid tumors. The main goals are to find safe dose levels and see if the treatment can shrink tumors. It is for peopl…

This study is testing whether a community program called Potlako+ can help people with possible cancer symptoms get diagnosed and treated faster. The program involves educating communities about cancer warning signs and providing patient navigators to guide people through the hea…

This study is testing a new cell therapy for people whose Hodgkin's or Non-Hodgkin's lymphoma has come back or hasn't responded to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to better target cancer cells, and then infuse them back into th…

This study is testing if a drug called bevacizumab can help adults with recurrent respiratory papillomatosis (RRP), a rare condition causing wart-like growths in the airways. Participants, who currently need surgery multiple times a year to clear these growths, will receive bevac…

This is a first-in-human study to test the safety and find the right dose of a new drug called GSK3745417. It is being tested alone and in combination with another cancer drug, dostarlimab, in adults with advanced solid tumors that have stopped responding to standard treatments. …

This study allows patients with ALK- or RET-positive cancers who benefited from alectinib or crizotinib in previous Roche trials to continue receiving the drug after those trials end. It aims to provide ongoing treatment access while monitoring safety in about 200 participants. T…

This study is testing whether new technology can make radiation therapy for lung cancer more precise. It aims to adjust the radiation beam in real-time to follow a tumor's movement as a patient breathes. The research involves 20 patients to see if this tracking method is practica…

This study is observing how well a combination of the drug Osimertinib and standard chemotherapy works for people with a specific type of advanced lung cancer (EGFR-positive NSCLC) in a real-world setting. It involves 532 adult patients who have already started this specific trea…

This is the first study in people to test a new immunotherapy drug called TSR-022. The main goals are to find a safe dose and see if the drug can help shrink tumors in adults with advanced cancers that have spread. The study will test TSR-022 by itself and combined with other can…

This study allows cancer patients who were benefiting from atezolizumab treatment in previous Roche-sponsored trials to continue receiving their medication if it's not available through regular channels. The 49 participants can keep getting their treatment while researchers monit…

This study tests an experimental treatment called Lete-Cel, which uses a patient's own genetically modified immune cells to fight two types of advanced soft tissue cancer: synovial sarcoma and myxoid/round cell liposarcoma. It involves 87 participants whose cancers have progresse…

This is a first-in-human study to find a safe dose of a new immunotherapy drug called BI 765179 for adults with advanced solid tumors. In the first part, researchers will test the drug alone and combined with another immunotherapy (ezabenlimab). In the second part, they will test…

This is the first study in humans of an experimental immunotherapy drug called dostarlimab for people with advanced solid tumors that have stopped responding to available treatments. The main goal is to find a safe dose and schedule for the drug and to check for early signs that …

This is an early-stage study testing a new immunotherapy drug called JNJ-63723283 in people with advanced cancers that have not responded to other treatments. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors in cancers like lung cancer…

This study is testing whether a special type of mammogram that uses contrast dye can find breast cancer better than standard mammograms in women who have already had breast cancer. Researchers are comparing the two methods in over 1,600 women during their annual screenings. The g…

This study is testing a new clinic program designed to help prevent dangerous blood clots in cancer patients who are starting treatment. It will see if training doctors and using a specific process leads to more patients being checked for clot risk and getting the right preventiv…

This study is testing whether a peer-led group program can help cancer survivors manage feelings of anxiety and depression after finishing their main cancer treatment. The program involves seven weekly group sessions led by trained non-professionals, focusing on building skills t…

This study is testing a new, culturally adapted exercise program designed for Hispanic prostate cancer survivors and the person who helps care for them. The program involves the survivor and caregiver working out together in remote group classes for three months. The main goal is…

This study provides standard cancer care and collects health information from patients at the National Cancer Institute who are not enrolled in other research trials. It aims to create a large database of patient experiences to help generate ideas for future cancer research. Part…

This study looks back at existing medical records to understand how blood clots are treated in people with cancer across Europe. Researchers are analyzing data from thousands of patients to see which blood-thinning medications work best, what side effects occur, and how much trea…

This study aims to see if providing standardized training to cancer doctors in smaller city and county hospitals leads to better testing and treatment for patients with advanced non-small cell lung cancer. It will follow 1,000 patients to measure if doctors order more recommended…

This study looks back at the medical records of 232 adults with cancer who were treated with an immunotherapy drug called M7824. The goal is to create a complete list of the side effects people experienced, including skin issues. By understanding these risks better, doctors hope …

This study tracks the long-term safety of experimental cancer treatments in patients who previously participated in earlier Janssen trials. It follows 80 people with various cancers to monitor for serious side effects over time. The goal is to better understand the safety profile…